Guggenheim assumed coverage on shares of Maze Therapeutics (NASDAQ:MAZE - Free Report) in a report released on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $19.00 price objective on the stock.
MAZE has been the topic of several other reports. JPMorgan Chase & Co. initiated coverage on Maze Therapeutics in a research report on Tuesday. They set an "overweight" rating and a $30.00 price objective on the stock. Leerink Partners initiated coverage on Maze Therapeutics in a research report on Tuesday. They set an "outperform" rating and a $28.00 price objective on the stock. Three investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $25.67.
View Our Latest Stock Report on MAZE
Maze Therapeutics Trading Down 3.9 %
MAZE traded down $0.49 during trading on Tuesday, reaching $12.23. The stock had a trading volume of 141,658 shares, compared to its average volume of 324,193. Maze Therapeutics has a one year low of $10.08 and a one year high of $17.00.
Maze Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Read More
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
